59 related articles for article (PubMed ID: 38561461)
1. Clinical and Pathologic Differences between Small-Cell Carcinoma and Large-Cell Neuroendocrine Carcinoma of the Lung.
Fujiwara W; Yotsukura M; Yoshida Y; Nakagawa K; Kashima J; Yatabe Y; Watanabe SI
Ann Surg Oncol; 2024 May; ():. PubMed ID: 38811497
[TBL] [Abstract][Full Text] [Related]
2. Different Characteristics and Survival between Surgically Resected Pure and Combined Pulmonary Large Cell Neuroendocrine Carcinoma.
Wang Y; Chen Y; Yang Z; Qian F; Hu M; Lu J; Zhang Y; Zhang W; Wang K; Han B
Ann Surg Oncol; 2022 Sep; 29(9):5666-5678. PubMed ID: 35543906
[TBL] [Abstract][Full Text] [Related]
3. Systemic treatment for neuroendocrine non-small cell lung carcinoma: A cases series and a systematic review of the literature.
Jelli B; Brandão M; Mekinda Z; Durieux V; Berghmans T
Lung Cancer; 2023 Jul; 181():107232. PubMed ID: 37216840
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of second-line chemotherapy in patients with pulmonary large cell neuroendocrine carcinoma.
Iida Y; Wakuda K; Kenmotsu H; Doshita K; Kodama H; Nishioka N; Miyawaki E; Miyawaki T; Mamesaya N; Kobayashi H; Omori S; Ko R; Ono A; Naito T; Murakami H; Sugino T; Gon Y; Takahashi T
Sci Rep; 2024 Apr; 14(1):7641. PubMed ID: 38561461
[TBL] [Abstract][Full Text] [Related]
5. Disparity in clinical outcomes between pure and combined pulmonary large-cell neuroendocrine carcinoma: A multi-center retrospective study.
Zhang JT; Li Y; Yan LX; Zhu ZF; Dong XR; Chu Q; Wu L; Zhang HM; Xu CW; Lin G; Yu ZY; Hu J; Zhu B; Wang HJ; Yang F; Song ZB; Han ZB; Li MX; Lin J; Wu YL; Wang JL; Zhong WZ
Lung Cancer; 2020 Jan; 139():118-123. PubMed ID: 31775086
[TBL] [Abstract][Full Text] [Related]
6. Clinical features of unresectable high-grade lung neuroendocrine carcinoma diagnosed using biopsy specimens.
Shimada Y; Niho S; Ishii G; Hishida T; Yoshida J; Nishimura M; Yoh K; Goto K; Ohmatsu H; Ohe Y; Nagai K
Lung Cancer; 2012 Mar; 75(3):368-73. PubMed ID: 21920624
[TBL] [Abstract][Full Text] [Related]
7. Clinical activity of pembrolizumab with or without chemotherapy in advanced pulmonary large-cell and large-cell neuroendocrine carcinomas: a multicenter retrospective cohort study.
Song L; Zhou F; Xu T; Zeng L; Xia Q; Wang Z; Deng L; Li Y; Qin H; Yan H; Huang Z; Mi J; Xu Q; Yang N; Zhou C; Zhang Y
BMC Cancer; 2023 May; 23(1):443. PubMed ID: 37189075
[TBL] [Abstract][Full Text] [Related]
8. Clinical features of large cell neuroendocrine carcinoma: a population-based overview.
Derks JL; Hendriks LE; Buikhuisen WA; Groen HJ; Thunnissen E; van Suylen RJ; Houben R; Damhuis RA; Speel EJ; Dingemans AM
Eur Respir J; 2016 Feb; 47(2):615-24. PubMed ID: 26541538
[TBL] [Abstract][Full Text] [Related]
9. DLL3 expression is a predictive marker of sensitivity to adjuvant chemotherapy for pulmonary LCNEC.
Ogawa H; Sakai Y; Nishio W; Fujibayashi Y; Nishikubo M; Nishioka Y; Tane S; Kitamura Y; Sudo T; Sakuma T; Yoshimura M
Thorac Cancer; 2020 Sep; 11(9):2561-2569. PubMed ID: 32691982
[TBL] [Abstract][Full Text] [Related]
10. Extensive-Stage Small-Cell Lung Cancer: First-Line and Second-Line Treatment Options.
Zugazagoitia J; Paz-Ares L
J Clin Oncol; 2022 Feb; 40(6):671-680. PubMed ID: 34985925
[TBL] [Abstract][Full Text] [Related]
11. Update in Interstitial Lung Disease 2020.
Podolanczuk AJ; Wong AW; Saito S; Lasky JA; Ryerson CJ; Eickelberg O
Am J Respir Crit Care Med; 2021 Jun; 203(11):1343-1352. PubMed ID: 33835899
[No Abstract] [Full Text] [Related]
12. Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial.
Baize N; Monnet I; Greillier L; Geier M; Lena H; Janicot H; Vergnenegre A; Crequit J; Lamy R; Auliac JB; Letreut J; Le Caer H; Gervais R; Dansin E; Madroszyk A; Renault PA; Le Garff G; Falchero L; Berard H; Schott R; Saulnier P; Chouaid C;
Lancet Oncol; 2020 Sep; 21(9):1224-1233. PubMed ID: 32888454
[TBL] [Abstract][Full Text] [Related]
13. Interstitial lung abnormalities detected incidentally on CT: a Position Paper from the Fleischner Society.
Hatabu H; Hunninghake GM; Richeldi L; Brown KK; Wells AU; Remy-Jardin M; Verschakelen J; Nicholson AG; Beasley MB; Christiani DC; San José Estépar R; Seo JB; Johkoh T; Sverzellati N; Ryerson CJ; Graham Barr R; Goo JM; Austin JHM; Powell CA; Lee KS; Inoue Y; Lynch DA
Lancet Respir Med; 2020 Jul; 8(7):726-737. PubMed ID: 32649920
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy for pulmonary large cell neuroendocrine carcinomas: does the regimen matter?
Derks JL; van Suylen RJ; Thunnissen E; den Bakker MA; Groen HJ; Smit EF; Damhuis RA; van den Broek EC; Speel EM; Dingemans AC;
Eur Respir J; 2017 Jun; 49(6):. PubMed ID: 28572122
[TBL] [Abstract][Full Text] [Related]
15. Amrubicin monotherapy may be an effective second-line treatment for patients with large-cell neuroendocrine carcinoma or high-grade non-small-cell neuroendocrine carcinoma.
Kasahara N; Wakuda K; Omori S; Nakashima K; Ono A; Taira T; Kenmotsu H; Naito T; Murakami H; Mori K; Watanabe R; Endo M; Nakajima T; Yamada M; Takahashi T
Mol Clin Oncol; 2017 May; 6(5):718-722. PubMed ID: 28529747
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
